Literature DB >> 17827009

Synthesis and structure-activity relationship of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitriles as EGFR tyrosine kinase inhibitors.

Madhavi Pannala1, Sunil Kher, Norma Wilson, John Gaudette, Ila Sircar, Shao-Hui Zhang, Alexei Bakhirev, Guang Yang, Phoebe Yuen, Frank Gorcsan, Naoki Sakurai, Miguel Barbosa, Jie-Fei Cheng.   

Abstract

Synthesis and structure-activity relationship of a series of 4-(2-aryl-cyclopropylamino)-quinoline-3-carbonitrile derivatives as EGFR inhibitors is described. Compounds 29 and 30 showed potent in vitro inhibitory activity in the enzymatic assay as well as in the functional cellular assay. They are moderately selective against other types of tyrosine kinases.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17827009     DOI： 10.1016/j.bmcl.2007.07.071

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  7 in total

1.  Synthesis and X-ray study of dispiro 8-nitroquinolone analogues and their cytotoxic properties against human cervical cancer HeLa cells.

Authors:  Selvaraj Shyamsivappan; Raju Vivek; Arjunan Saravanan; Thangaraj Arasakumar; Gopalan Subashini; Thangaraj Suresh; Ramasamy Shankar; Palathurai Subramaniam Mohan
Journal:  Medchemcomm       Date:  2019-01-22       Impact factor: 3.597

2.  Discovery of 4-alkoxy-2-aryl-6,7-dimethoxyquinolines as a new class of topoisomerase I inhibitors endowed with potent in vitro anticancer activity.

Authors:  Mostafa M Elbadawi; Wagdy M Eldehna; Wenjie Wang; Keli K Agama; Yves Pommier; Manabu Abe
Journal:  Eur J Med Chem       Date:  2021-02-09       Impact factor: 7.088

3.  New arylated benzo[h]quinolines induce anti-cancer activity by oxidative stress-mediated DNA damage.

Authors:  Dharmendra K Yadav; Reeta Rai; Naresh Kumar; Surjeet Singh; Sanjeev Misra; Praveen Sharma; Priyanka Shaw; Horacio Pérez-Sánchez; Ricardo L Mancera; Eun Ha Choi; Mi-Hyun Kim; Ramendra Pratap
Journal:  Sci Rep       Date:  2016-12-06       Impact factor: 4.379

4.  2-Arylquinolines as novel anticancer agents with dual EGFR/FAK kinase inhibitory activity: synthesis, biological evaluation, and molecular modelling insights.

Authors:  Mostafa M Elbadawi; Wagdy M Eldehna; Amer Ali Abd El-Hafeez; Warda R Somaa; Amgad Albohy; Sara T Al-Rashood; Keli K Agama; Eslam B Elkaeed; Pradipta Ghosh; Yves Pommier; Manabu Abe
Journal:  J Enzyme Inhib Med Chem       Date:  2022-12       Impact factor: 5.051

5.  Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches.

Authors:  Xiaocong Pang; Wenwen Lian; Lvjie Xu; Jinhua Wang; Hao Jia; Baoyue Zhang; Ai-Lin Liu; Guan-Hua Du
Journal:  RSC Adv       Date:  2018-01-30       Impact factor: 4.036

6.  Synthesis of some novel 2-(3-cyano -6-(thiophen- 2-yl)-4,4'- bipyridin-2- yloxy)acetohydrazide derivatives: assessment of their cytotoxic activity.

Authors:  Hossa F Al Shareef
Journal:  BMC Chem       Date:  2020-06-02

Review 7.  Quinoline-Based Molecules Targeting c-Met, EGF, and VEGF Receptors and the Proteins Involved in Related Carcinogenic Pathways.

Authors:  Annamaria Martorana; Gabriele La Monica; Antonino Lauria
Journal:  Molecules       Date:  2020-09-18       Impact factor: 4.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.